Marios Politis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1691722/publications.pdf

Version: 2024-02-01

127 papers	8,968 citations	44069 48 h-index	45317 90 g-index
130 all docs	130 docs citations	130 times ranked	10430 citing authors

#	Article	IF	Citations
1	Imaging in Huntingtonâ€™s. Neuromethods, 2022, , 457-505.	0.3	0
2	Predictors of RBD progression and conversion to synucleinopathies. Current Neurology and Neuroscience Reports, 2022, 22, 93-104.	4.2	13
3	Recent Advances in Neuroimaging Techniques to Assist Clinical Trials on Cell-Based Therapies in Neurodegenerative Diseases. Stem Cells, 2022, 40, 724-735.	3.2	1
4	Aquaporin-4 polymorphisms predict amyloid burden and clinical outcome in the Alzheimer's disease spectrum. Neurobiology of Aging, 2021, 97, 1-9.	3.1	40
5	Serotonergic imaging in Parkinson's disease. Progress in Brain Research, 2021, 261, 303-338.	1.4	11
6	Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 179, 189-205.	1.8	12
7	Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimerâ€™s Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 82, 541-560.	2.6	18
8	The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 77, 163-169.	2.2	11
9	[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 366-378.	6.4	19
10	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurology, The, 2020, 19, 71-80.	10.2	94
11	Predict cognitive decline with clinical markers in Parkinsonâ€™s disease (PRECODE-1). Journal of Neural Transmission, 2020, 127, 51-59.	2.8	6
12	Longitudinal Measurements of Glucocerebrosidase activity in Parkinsonâ€™s patients. Annals of Clinical and Translational Neurology, 2020, 7, 1816-1830.	3.7	23
13	Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases. Cells, 2020, 9, 2581.	4.1	20
14	Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle <scp>2A</scp> in Early <scp>Drugâ€Naive</scp> Parkinson's Disease. Movement Disorders, 2020, 35, 1416-1427.	3.9	48
15	Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications. Journal of Neurology, 2020, 267, 2042-2053.	3.6	20
16	Neuroimaging in Lewy body dementia. Journal of Neurology, 2019, 266, 1-26.	3.6	45
17	Magnetic resonance imaging in Alzheimerâ€™s disease and mild cognitive impairment. Journal of Neurology, 2019, 266, 1293-1302.	3.6	196
18	Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naÃ¯ve Parkinsonâ€™s patients. PLoS ONE, 2019, 14, e0214352.	2.5	12

#	Article	IF	Citations
19	Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. Human Brain Mapping, 2019, 40, 5424-5442.	3.6	127
20	Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinsonâ€™s disease. BMC Neuroscience, 2019, 20, 55.	1.9	9
21	Imidazoline 2 binding sites reflecting astroglia pathology in Parkinsonâ€™s disease: an in vivo11C-BU99008 PET study. Brain, 2019, 142, 3116-3128.	7.6	73
22	Cortical thinning across Parkinson's disease stages and clinical correlates. Journal of the Neurological Sciences, 2019, 398, 31-38.	0.6	51
23	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). Parkinsonism and Related Disorders, 2019, 62, 201-209.	2.2	15
24	Serotonergic pathology and disease burden in the premotor and motor phase of A53T Î±-synuclein parkinsonism: a cross-sectional study. Lancet Neurology, The, 2019, 18, 748-759.	10.2	70
25	Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. Movement Disorders, 2019, 34, 1505-1515.	3.9	15
26	Speech difficulties in early de novo patients with Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 256-261.	2.2	26
27	Predicting cognitive decline with non-clinical markers in Parkinsonâ€™s disease (PRECODE-2). Journal of Neurology, 2019, 266, 1203-1210.	3.6	14
28	Dementia spectrum disorders: lessons learnt from decades with PET research. Journal of Neural Transmission, 2019, 126, 233-251.	2.8	32
29	Hybrid PET-MRI Applications in Movement Disorders. International Review of Neurobiology, 2019, 144, 211-257.	2.0	14
30	Molecular Imaging of Dementia With Lewy Bodies. International Review of Neurobiology, 2019, 144, 59-93.	2.0	10
31	Cerebral serotonin transporter measurements with [¹¹C]DASB: A review on acquisition and preprocessing across 21 PET centres. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 210-222.	4.3	25
32	Serotonergic dysregulation is linked to sleep problems in Parkinson's disease. NeuroImage: Clinical, 2018, 18, 630-637.	2.7	52
33	Diabetes mellitus and Parkinson disease. Neurology, 2018, 90, e1654-e1662.	1.1	158
34	Dopamine reuptake transporterâ€“singleâ€photon emission computed tomography and transcranial sonography as imaging markers of prediagnostic Parkinson's disease. Movement Disorders, 2018, 33, 478-482.	3.9	25
35	The serotonergic system in Parkinsonâ€™s patients with dyskinesia: evidence from imaging studies. Journal of Neural Transmission, 2018, 125, 1217-1223.	2.8	26
36	Increased dopaminergic function in the thalamus is associated with excessive daytime sleepiness. Sleep Medicine, 2018, 43, 25-30.	1.6	12

#	Article	IF	Citations
37	Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinsonâ€™s disease. Brain, 2018, 141, 1501-1516.	7.6	148
38	Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. Journal of the Neurological Sciences, 2018, 387, 220-227.	0.6	51
39	¹¹Câ€PE2I and ¹⁸Fâ€Dopa PET for assessing progression rate in Parkinson's: A longitudinal study. Movement Disorders, 2018, 33, 117-127.	3.9	45
40	Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 185-196.	1.9	18
41	Imaging Transplantation in Movement Disorders. International Review of Neurobiology, 2018, 143, 213-263.	2.0	6
42	Neuroimaging of Sleep Disturbances in Movement Disorders. Frontiers in Neurology, 2018, 9, 767.	2.4	15
43	Structural Magnetic Resonance Imaging in Huntington's Disease. International Review of Neurobiology, 2018, 142, 335-380.	2.0	14
44	Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease. International Review of Neurobiology, 2018, 141, 131-172.	2.0	18
45	Molecular Imaging in Huntington's Disease. International Review of Neurobiology, 2018, 142, 289-333.	2.0	6
46	PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. Movement Disorders, 2018, 33, 1961-1965.	3.9	38
47	Molecular Imaging of the Serotonergic System in Parkinson's Disease. International Review of Neurobiology, 2018, 141, 173-210.	2.0	24
48	Advances in MRI Methodology. International Review of Neurobiology, 2018, 141, 31-76.	2.0	124
49	Disease-related patterns of in vivo pathology in Corticobasal syndrome. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2413-2425.	6.4	26
50	Imaging Markers of Progression in Parkinson's Disease. Movement Disorders Clinical Practice, 2018, 5, 586-596.	1.5	23
51	REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology, 2018, 91, e894-e905.	1.1	112
52	The psychosis spectrum in Parkinson disease. Nature Reviews Neurology, 2017, 13, 81-95.	10.1	252
53	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Movement Disorders, 2017, 32, 181-192.	3.9	88
54	Cognitive decline in Parkinson disease. Nature Reviews Neurology, 2017, 13, 217-231.	10.1	705

#	Article	IF	Citations
55	Urinary dysfunction in early de novo patients with Parkinson's disease. Movement Disorders, 2017, 32, 939-940.	3.9	9
56	Disease progression in LRRK2 parkinsonism. Lancet Neurology, The, 2017, 16, 334-335.	10.2	1
57	Imaging in Parkinson's Disease. International Review of Neurobiology, 2017, 132, 233-274.	2.0	21
58	Serotonin transporter in Parkinson's disease: A metaâ€analysis of positron emission tomography studies. Annals of Neurology, 2017, 81, 171-180.	5.3	77
59	A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism (Niccolini and Politis, 2016). European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 548-550.	6.4	0
60	PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinsonâ€™s Disease. Current Neurology and Neuroscience Reports, 2017, 17, 90.	4.2	20
61	Chronic exposure to dopamine agonists affects the integrity of striatal D 2 receptors in Parkinson's patients. NeuroImage: Clinical, 2017, 16, 455-460.	2.7	33
62	Loss of phosphodiesterase 4 in Parkinson disease. Neurology, 2017, 89, 586-593.	1.1	30
63	Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. Movement Disorders, 2017, 32, 235-240.	3.9	18
64	Molecular Imaging Markers to Track Huntingtonâ€™s Disease Pathology. Frontiers in Neurology, 2017, 8, 11.	2.4	44
65	Imaging the Nonmotor Symptoms in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 179-257.	2.0	14
66	Be vigilant for dementia in Parkinsonâ€™s disease. Practitioner, 2017, 261, 11-5.	0.3	27
67	Parkinson';s Disease, Diabetes and Cognitive Impairment. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2016, 10, 11-21.	0.6	52
68	Current status of PET imaging in Huntingtonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1171-1182.	6.4	66
69	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. Journal of the Neurological Sciences, 2016, 368, 243-248.	0.6	37
70	A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2244-2254.	6.4	37
71	Imaging in Parkinsonâ€™s disease. Clinical Medicine, 2016, 16, 371-375.	1.9	110
72	Serotonergic loss underlying apathy in Parkinsonâ€™s disease. Brain, 2016, 139, 2338-2339.	7.6	9

#	Article	IF	Citations
73	Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study. Movement Disorders, 2016, 31, 1020-1026.	3.9	49
74	Cholinergic imaging in dementia spectrum disorders. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1376-1386.	6.4	87
75	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [¹¹C]IMA107. American Journal of Psychiatry, 2016, 173, 714-721.	7.2	33
76	Serotonin-to-dopamine transporter ratios in Parkinson disease. Neurology, 2016, 86, 1152-1158.	1.1	71
77	Altered PDE10A expression detectable early before symptomatic onset in Huntingtonâ€™s disease. Brain, 2015, 138, 3016-3029.	7.6	90
78	Morphometric changes in the reward system of Parkinsonâ€™s disease patients with impulse control disorders. Journal of Neurology, 2015, 262, 2653-2661.	3.6	41
79	Molecular imaging of levodopa-induced dyskinesias. Cellular and Molecular Life Sciences, 2015, 72, 2107-2117.	5.4	18
80	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinsonâ€™s disease. Brain, 2015, 138, 3003-3015.	7.6	100
81	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. Neurobiology of Aging, 2015, 36, 1736-1742.	3.1	42
82	Single versus multiple impulse control disorders in Parkinsonâ€™s disease: an 11C-raclopride positron emission tomography study of reward cue-evoked striatal dopamine release. Journal of Neurology, 2015, 262, 1504-1514.	3.6	41
83	PET in Multiple Sclerosis. Clinical Nuclear Medicine, 2015, 40, e46-e52.	1.3	20
84	Recent imaging advances in neurology. Journal of Neurology, 2015, 262, 2182-2194.	3.6	33
85	Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. Neurobiology of Disease, 2015, 83, 115-121.	4.4	133
86	Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome. Parkinsonism and Related Disorders, 2015, 21, 1336-1341.	2.2	9
87	SEROTONIN-TO-DOPAMINE TRANSPORTER RATIOS IN THE STRIATUM OF PATIENTS WITH PARKINSON'S DISEASE: IMPACT ON LEVODOPAâ€“INDUCED DYSKINESIAS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.96-e4.	1.9	0
88	Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. Brain, 2015, 138, 110-119.	7.6	76
89	The X-Linked Hypothesis of Brain Disorders. Neuroscientist, 2015, 21, 589-598.	3.5	1
90	Serotonin in Parkinson's disease. Behavioural Brain Research, 2015, 277, 136-145.	2.2	224

#	Article	IF	Citations
91	Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinsonâ€™s disease patients. Journal of Clinical Investigation, 2014, 124, 1340-1349.	8.2	202
92	Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. Aids, 2014, 28, 67-72.	2.2	128
93	Long-term Clinical Outcome of Fetal Cell Transplantation for Parkinson Disease. JAMA Neurology, 2014, 71, 83.	9.0	257
94	Dopamine receptor mapping with PET imaging in Parkinsonâ€™s disease. Journal of Neurology, 2014, 261, 2251-2263.	3.6	45
95	Neuroimaging in Parkinson disease: from research setting to clinical practice. Nature Reviews Neurology, 2014, 10, 708-722.	10.1	195
96	Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: An in vivo [(11)C](R)-PK11195-PET pilot study. Neurobiology of Disease, 2014, 65, 203-210.	4.4	66
97	Problematic Internet use in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 482-487.	2.2	13
98	Neuroimaging in Huntingtonâ€™s disease. World Journal of Radiology, 2014, 6, 301.	1.1	60
99	Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinsonâ€™s disease. Brain, 2013, 136, 400-411.	7.6	172
100	Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology, 2013, 80, 1850-1855.	1.1	95
101	Ambient particulate matter and its potential neurological consequences. Reviews in the Neurosciences, 2013, 24, 323-35.	2.9	36
102	Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes. Degenerative Neurological and Neuromuscular Disease, 2013, 3, 33.	1.3	9
103	Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinsonâ€™s Patients Treated with Dopamine Grafts. Science Translational Medicine, 2012, 4, 128ra41.	12.4	107
104	Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology, 2012, 79, 523-530.	1.1	150
105	The catechol-O-methyltransferase Val158Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinsonâ€™s disease: a PET study. Brain, 2012, 135, 2449-2457.	7.6	56
106	Reduplicative Paramnesia: A Review. Psychopathology, 2012, 45, 337-343.	1.5	24
107	Impulse Control Disorders in Parkinsonâ€™s Disease: A Review. Current Psychiatry Reviews, 2012, 8, 235-246.	0.9	1
108	Imaging of microglia in patients with neurodegenerative disorders. Frontiers in Pharmacology, 2012, 3, 96.	3.5	98

#	Article	IF	Citations
109	Positron emission tomography imaging in neurological disorders. Journal of Neurology, 2012, 259, 1769-1780.	3.6	75
110	In vivo imaging of the integration and function of nigral grafts in clinical trials. Progress in Brain Research, 2012, 200, 199-220.	1.4	16
111	Acute HCV/HIV Coinfection Is Associated with Cognitive Dysfunction and Cerebral Metabolite Disturbance, but Not Increased Microglial Cell Activation. PLoS ONE, 2012, 7, e38980.	2.5	30
112	Clinical application of stem cell therapy in Parkinson's disease. BMC Medicine, 2012, 10, 1.	5.5	285
113	Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain, 2011, 134, 969-978.	7.6	283
114	Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability. Scientific World Journal, The, 2011, 11, 1726-1734.	2.1	76
115	Serotonergic mediated body mass index changes in Parkinson's disease. Neurobiology of Disease, 2011, 43, 609-615.	4.4	40
116	Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease. BMC Medicine, 2011, 9, 50.	5.5	13
117	Graftâ€induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Movement Disorders, 2011, 26, 1997-2003.	3.9	151
118	Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study. Human Brain Mapping, 2011, 32, 258-270.	3.6	181
119	Positron emission tomography neuroimaging in Parkinson's disease. American Journal of Translational Research (discontinued), 2011, 3, 323-41.	0.0	48
120	Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiology of Disease, 2010, 37, 356-361.	4.4	56
121	Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study. Neurobiology of Disease, 2010, 40, 216-221.	4.4	213
122	Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?. BMC Medicine, 2010, 8, 80.	5.5	46
123	Parkinson's disease symptoms: The patient's perspective. Movement Disorders, 2010, 25, 1646-1651.	3.9	464
124	Brain imaging after neural transplantation. Progress in Brain Research, 2010, 184, 193-203.	1.4	19
125	Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinsonâ€™s Patients with Neural Transplants. Science Translational Medicine, 2010, 2, 38ra46.	12.4	272
126	Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride PET study. Experimental Neurology, 2008, 214, 112-116.	4.1	101

#	Article	IF	Citations
127	Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain, 2008, 131, 2860-2869.	7.6	155